Jian Campian

Mayo Clinic — United States

Medicine · Health Sciences

39h-index7.1kcitations269works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(144), Brain Metastases and Treatment(58), Cancer Immunotherapy and Biomarkers(41), Inflammatory Biomarkers in Disease Prognosis(26), CAR-T cell therapy research(25)

Publications266 total

Daily locomotor activity declines with tumor growth and disease progression in glioblastoma
JCI Insight·2025Open Access
PATH-100. High-Grade Astrocytoma with Piloid Features: An institutional experience
Neuro-Oncology·2025Open Access
PATH-12. Pembrolizumab efficacy in recurrent adult-type diffuse gliomas
Neuro-Oncology·2025Open Access
NCOG-27. Neuro-oncology anywhere: A fully decentralized clinical trial evaluating cognitive assessments and interventions for patients who received intracranial radiation therapy
Neuro-Oncology·2025Open Access
EXTH-42. Lost in translation: Do preclinical studies predict clinical failure in GBM?
Neuro-Oncology·2025Open Access
INNV-26. Neuro-oncology anywhere (NOA) 242: Interim results from a pragmatic clinical trial evaluating telehealth versus in-person evaluations for individuals with glioma undergoing oral chemotherapy
Neuro-Oncology·2025Open Access
490 Laser interstitial thermal therapy plus pembrolizumab extends survival and ignites anti-tumor immunity in recurrent high-grade astrocytoma: results from a phase 1/randomized phase 2b trial
Regular and Young Investigator Award Abstracts·2025Open Access
CTIM-11. LASER INTERSTITIAL THERMAL THERAPY PLUS PEMBROLIZUMAB PROLONGS SURVIVAL AND ELICITS ROBUST ANTI-TUMOR IMMUNITY IN RECURRENT, REFRACTORY HIGH-GRADE ASTROCYTOMA: A PHASE 1/RANDOMIZED PHASE 2B TRIAL
Neuro-Oncology·2025Open Access
CNSC-45. DAILY LOCOMOTOR ACTIVITY DECLINES WITH TUMOR GROWTH AND PRECEDES CLINICAL DETECTION OF PROGRESSION IN GLIOBLASTOMA
Neuro-Oncology·2025Open Access
NCOG-44. Experience with vorasidenib in patients with grade 3 or 4 IDH-mutant gliomas
Neuro-Oncology·2025
CTNI-08. WSD0922-FU THERAPY IN PATIENTS WITH EGFR MUTANT GLIOBLASTOMA – UPDATES FROM THE DOSE EXPANSION COHORTS OF A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL (MC1914)
Neuro-Oncology·2025Open Access
407 Relationships between lymphocyte counts and clinical outcomes in patients with recurrent glioblastoma treated with pembrolizumab
Regular and Young Investigator Award Abstracts·2025Open Access
TMOD-32. Novel immunocytokine CD80/IL2v synergizes with α-PD-1 for treatment of preclinical murine glioblastoma models
Neuro-Oncology·2025Open Access
NCOG-32. Clinical outcomes of combination PARP inhibitor and temozolomide therapy in recurrent glioma: Insights from a single institution experience
Neuro-Oncology·2025Open Access
BIOM-91. RELATIONSHIPS BETWEEN LYMPHOCYTE COUNTS AND CLINICAL OUTCOMES IN PATIENTS WITH GLIOMAS TREATED WITH PEMBROLIZUMAB
Neuro-Oncology·2025Open Access
CTIM-33. PERSONALIZED MULTIVALENT DNA VACCINATION SAFELY INDUCES BROAD NEOANTIGEN-SPECIFIC T CELL RESPONSES IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN A CLINICALLY RELEVANT TIME SCALE
Neuro-Oncology·2025Open Access
IMG-26. Clinical utility of RANO 2.0 for response assessment to immunotherapy in recurrent gliomas
Neuro-Oncology·2025
Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas
Neuro-Oncology·2025
A phase I window-of-opportunity study of neoadjuvant avelumab and hypofractionated radiation therapy in radiation-relapsed meningioma
2025Open Access
Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma
Current Oncology·2025Open Access
page 1 of 14Next →

Frequent Co-authors

Jiayi Huang(14), Albert H. Kim(9), Stuart A. Grossman(7), David D. Tran(6), Xiaobu Ye(6), Omar H. Butt(6), Nicholas Butowski(5), Samuel Goldlust(5), Karen Fink(5), Manmeet S. Ahluwalia(5), George Ansstas(5), John W. Eaton(5), T.A. DeWees(5), Yuan James Rao(5), Alexander J. Lin(5), Dennis E. Hallahan(5), David Tran(4), Fábio M. Iwamoto(4), Glenn J. Lesser(4), Andrew E. Sloan(4)